News

Chemestmed presentation at the 8th Neurological Disorders Summit (NDS-2023) Rome (Italy) June 12-14, 2023

14.06.2023

The CEO Dr. Neinar Seli and Professor Mati Karelson presented Chemestmed’s new results on unique proprietary RNA m6A activators in neuroscience titled as “Neuroprotective agents based on RNA m6A regulation”

Chemestmed reports remarkable neuroprotective effects of our unique RNA m6A methyltransferase METTL3/METTL14/WTAP activators

26.07.2023

In a preprint deposited in Cold Spring Harbor Laboratory server bioRxiv, Chemestmed reports in collaboration with the Universities of Tartu and Helsinki remarkable neuroprotective effects of our unique RNA m6A methyltransferase METTL3/METTL14/WTAP activators in vitro and in vivo PD animal model.

Silver Saarva joins the Chemestmed's team

05.07.2023

Silver Saarva joins Chemestmed as an expert in relations with Asian biotech and pharmaceutical companies and academic research institutions. He has spent last 20 years in Asia, mostly in Chinese language environment and speaks fluent Mandarin and Indonesian.

Chemestmed signs a Consultancy Agreement with FreeMind Group LLC (Delaware, USA)

27.04.2023

This Agreement considers Argentum’s service on exploring and identifying non-dilutive funding sources and preparing and filing award applications for research and development (or other similarly natured) funding opportunities (grants and contracts) from funding agencies including but not limited to U.S. Federal sources such as NIH, BARDA, and DOD and Private Foundations:

Chemestmed signs a Professional Service Agreement with Argentum Europe, Ltd (Jerusalem, Israel)

27.04.2023

This Agreement considers Argentum’s service on exploring and identifying non-dilutive funding opportunities and preparing and filing applications for research and development funding opportunities (grants) from Funding Programs managed and funded by the European Union or by European and Associated Governments.

Chemestmed presentation at the Cold Spring Harbor (USA) meeting “Neurodegenerative Diseases: Biology & Therapeutics” November 30 - December 3, 2022

03.12.2022

The CEO Dr. Neinar Seli and Professor Mati Karelson presented Chemestmed’s groundbreaking results on unique proprietary RNA m6A activators in neuroscience titled as “Neuroprotective agents based on RNA m6A regulation”

 

Service agreement with Admescope OY

22.07.2021

Chemestmed, Ltd. and Admescope OY (Finland) signed the service agreements on the in vivo pharmacokinetics of two compounds after oral and IV administration to mice and rats.  

Agreement with the University of Helsinki

17.05.2021

Chemestmed, Ltd. and the University of Helsinki signed the research agreement “METTL3 small-molecule ligand screening”.

Chemestmed participated in the partnering eventa

22.03.2021

Chemestmed, Ltd. participates in the partnering event BioEurope 2021. 

Chemestmed signed research agreement

19.02.2021

Chemestmed, Ltd. and the University of Helsinki signed the research agreement Effects of m6A regulators on neurons and pancreatic beta cells”.

Chemestmed signed agreement with the University of Tartu

04.12.2020

Chemestmed, Ltd. and the University of Tartu signed the extension of the research agreement “Therapeutic ligands for RNA-epigenetic enzyme targets”.

Discovery of the first RNA m6A activator compounds

26.03.2019

Chemical modifications of RNA provide an additional epitranscriptomic level of control over cellular functions. N-6-methylated adenosines (m6As) are found in several types of RNA and their amounts are regulated by methyltransferases and demethylases.